GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Brooks Laboratories Ltd (NSE:BROOKS) » Definitions » Forward PE Ratio

Brooks Laboratories (NSE:BROOKS) Forward PE Ratio : 0.00 (As of May. 10, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Brooks Laboratories Forward PE Ratio?

Brooks Laboratories's Forward PE Ratio for today is 0.00.

Brooks Laboratories's PE Ratio without NRI for today is 0.00.

Brooks Laboratories's PE Ratio (TTM) for today is 0.00.


Brooks Laboratories Forward PE Ratio Historical Data

The historical data trend for Brooks Laboratories's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brooks Laboratories Forward PE Ratio Chart

Brooks Laboratories Annual Data
Trend
Forward PE Ratio

Brooks Laboratories Quarterly Data
Forward PE Ratio

Competitive Comparison of Brooks Laboratories's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brooks Laboratories's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Brooks Laboratories's Forward PE Ratio falls into.


;
;

Brooks Laboratories Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Brooks Laboratories  (NSE:BROOKS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Brooks Laboratories Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Brooks Laboratories's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Brooks Laboratories Business Description

Traded in Other Exchanges
Address
Off. Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093
Brooks Laboratories Ltd is an Indian company operating in the healthcare sector. The company is engaged in the formulation, development, production, and export of drugs and pharmaceuticals. The company operates under one segment: Pharmaceutical products including ingredients and intermediaries. It manufactures drugs in a variety of forms, including tablets, dry syrup, injections, liquid injections, dry powder injections, eye drops, and ear drops. Its products include carbapenem and penicillins.

Brooks Laboratories Headlines

No Headlines